EGFR and cancer: Nanobodies, such as those against EGFR [12], Her2 [19], VEGFR2 [20], c-Met [21], CXCR7 and MUC-1 [22], targeting transmembrane proteins and extracellular tumor-specific glycoproteins for cancer therapy, can be coupled with effector domain like toxins.